Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-02-25
2009-08-11
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S263100, C514S263200, C514S263300, C514S263400
Reexamination Certificate
active
07572800
ABSTRACT:
The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering FTC in combination or alternation with penciclovir, famciclovir or Bis-POM-PMEA. Additionally, the invention is directed to a method for treating hepatitis B virus infection comprising administering L-FMAU in combination or alternation with DAPD, penciclovir or Bis-POM-PMEA. The invention is further directed to a method for treating hepatitis B virus infection comprising administering DAPD in combination or alternation with Bis-POM-PMEA.
REFERENCES:
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 5075445 (1991-12-01), Jarvest et al.
patent: 5142051 (1992-08-01), Holy et al.
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5179104 (1993-01-01), Chu et al.
patent: 5194654 (1993-03-01), Hostetler et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5223263 (1993-06-01), Hostetler et al.
patent: 5234913 (1993-08-01), Furman et al.
patent: 5256641 (1993-10-01), Yatvin et al.
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5444063 (1995-08-01), Schinazi
patent: 5463092 (1995-10-01), Hostetler et al.
patent: 5486520 (1996-01-01), Belleau et al.
patent: 5538975 (1996-07-01), Dionne
patent: 5539116 (1996-07-01), Liotta et al.
patent: 5543389 (1996-08-01), Yatvin et al.
patent: 5543390 (1996-08-01), Yatvin et al.
patent: 5543391 (1996-08-01), Yatvin et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5565438 (1996-10-01), Chu et al.
patent: 5567688 (1996-10-01), Chu et al.
patent: 5587362 (1996-12-01), Chu et al.
patent: 5618820 (1997-04-01), Dionne
patent: 5641763 (1997-06-01), Holy et al.
patent: 5674849 (1997-10-01), Twist et al.
patent: 5674869 (1997-10-01), Kenig et al.
patent: 5684010 (1997-11-01), Schinazi
patent: 5684153 (1997-11-01), Geen et al.
patent: 5700937 (1997-12-01), Liotta et al.
patent: 5728575 (1998-03-01), Liotta et al.
patent: 5756478 (1998-05-01), Cheng et al.
patent: 5767122 (1998-06-01), Chu et al.
patent: 5808040 (1998-09-01), Chu et al.
patent: 5814639 (1998-09-01), Liotta et al.
patent: 5827727 (1998-10-01), Liotta et al.
patent: 5869461 (1999-02-01), Cheng et al.
patent: 5914331 (1999-06-01), Liotta et al.
patent: 6071922 (2000-06-01), Schinazi et al.
patent: 6177435 (2001-01-01), Larder et al.
patent: 6232300 (2001-05-01), Schinazi et al.
patent: 0 141 927 (1985-05-01), None
patent: 0 253 412 (1988-01-01), None
patent: 0 388 049 (1990-09-01), None
patent: 0 494 119 (1992-03-01), None
patent: 0 494 119 (1992-07-01), None
patent: 0 515 144 (1992-11-01), None
patent: 0 382 526 (1996-05-01), None
patent: 0 711 771 (1996-05-01), None
patent: WO 89/02733 (1989-04-01), None
patent: WO 90/00555 (1990-01-01), None
patent: WO 91/16920 (1991-11-01), None
patent: WO 91/17159 (1991-11-01), None
patent: WO 91/18914 (1991-12-01), None
patent: WO 91/19721 (1991-12-01), None
patent: WO 92/18517 (1992-10-01), None
patent: WO 93/00910 (1993-01-01), None
patent: WO 94/09793 (1994-05-01), None
patent: WO 94/26273 (1994-11-01), None
patent: WO 95/20595 (1995-08-01), None
patent: WO 98/23285 (1998-06-01), None
Chang et al.; “Deoxycytidine Deaminase-resistant Sterioisomer is the Active Form of (±)-2′,3′-Dideoxy-3′-thiacytidine in the Inhibition of Hepatitis B Virus Replication;” Journal of Biological Chemistry, vol. 267(20); pp. 13938-13942 (1992).
Davisson et al.; “Synthesis of Nucleotide 5′-Diphosphates from 5′-0-Tosyl Nucleosides;” J. Org. Chem 52(9); pp. 1794-1801 (1987).
Furman et al.; “The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (−) and (+) Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1, 3-oxathiolane-5-yl] Cytosine;” Antimicrobial Agents and Chemotherapy, Dec. 1992, pp. 2686-2692.
Hoard et al.; Conversion of Mono- and Oligodeoxyribonucleotides to 5′-Triphosphates; J. Am. Chem. Soc.; 87(8); pp. 1785-1788 (1965).
Imai et al.; “Studies on Phosphorylation. IV. Selective Phosphorylation of the Primary Hydroxyl Group in Nucleosides;” J. Org. Chem.; 34(6); pp. 1547-1550; (Jun. 1969).
Korba; “In vitro evaluation of combination therapies against hepatitis B virus replication;” Antiviral Res. 29; pp. 49-51; (1996).
Korba and Gerin; “Use of standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication;” Antiviral Res. 19; pp. 55-70; (1992).
Medline Abstract; AN; 96300556; 1996; Korba et al.
Medline Abstract; AN 97271965; 1997; Kruger et al.
Migyoung, L.; “Dioxolane Cytosine Nucleosides as Anti-Hepatitis B Agents;” Bioorganic & Medicinal C Chemistry Letters; 5, 17; pp. 2011-2014; 1995.
R. Jones and N. Bischofberger; “Minireview: nucleotide prodrugs;” Antiviral Research; 27; (1995); pp. 1-17.
Von Janta-Lipinski et al.; “Newly Synthesized L-Enantiomers of 3′Fluoro-Modified B-2′-Deoxyribonucleoside 5′-Triphosphates Inhibit Hepatitis B DNA Polymerases But Not the Five Cellular DNA Polymerases a, B, v, d, and e Nor HIV-1 Reverse Transcriptase;” J. Med. Chem.; 1998; 41; pp. 2040-2046.
Osborn et al., “Antiviral options for the treatment of chronic hepatitis B,” Journal of Antimicrobial Chemotherapy, vol. 57, pp. 1030-1034, Apr. 4, 2006.
Barry David W.
Furman Phillip A.
Painter, III George R.
Rousseau Franck
Gilead Sciences, Inc.
King & Spalding LLP
Sonnenfeld Kenneth H.
Wang Shengjun
Willis Michael A.
LandOfFree
Combination therapy to treat hepatitis B virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy to treat hepatitis B virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy to treat hepatitis B virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4113280